Zymeworks Highlights Its Upcoming Investor Conferences
Zymeworks Inc., a notable player in the clinical-stage biotechnology sector, is excited to connect with investors through several upcoming conferences. This engagement is crucial for the company’s vision of transforming the treatment landscape for tough diseases, particularly cancer and autoimmune disorders.
Planned Participation in Key Events
The management team at Zymeworks is set to participate in several high-profile investor conferences, providing them an excellent platform to discuss their innovative pipeline and future endeavors:
Jefferies Global Healthcare Conference
On June 4, Zymeworks’ management will engage in one-on-one meetings and will participate in a fireside chat scheduled for 2:35 pm Eastern Time in New York. This event presents a key opportunity to detail the progress of their projects and interact directly with investors.
Goldman Sachs Global Healthcare Conference
Shortly afterward, on June 11 at 2:00 pm Eastern Time, the team will again communicate their advancements at the Goldman Sachs Global Healthcare Conference, also through one-on-one meetings and a fireside chat, this time in Miami.
Citi European Healthcare Conference
Finally, on June 17, the management will take part in one-on-one meetings during the Citi European Healthcare Conference in London, fostering connections and sharing insights about Zymeworks’ commitment to healthcare advancement.
About Zymeworks Inc.
Zymeworks stands out as a global leader in developing multifunctional biotherapeutics aimed at tackling complex diseases. Their mission extends towards making meaningful contributions to improve the lives of patients facing serious health challenges, particularly in the realms of cancer and autoimmune diseases.
With an impressive array of therapeutic platforms and a fully integrated drug development engine, Zymeworks forges paths towards innovative antibody-based treatments. The company has made significant strides with zanidatamab, a HER2-targeted bispecific antibody created using their proprietary Azymetric™ technology.
The pivotal moment came with the accelerated approval of Ziihera® (zanidatamab-hrii), marked as the first dual HER2-targeted bispecific antibody approved for patients with previously treated, unresectable, or metastatic HER2-positive second-line biliary tract cancer in the U.S.
Moreover, zanidatamab is currently undergoing regulatory assessments in Europe and China, affirming Zymeworks’ commitment to expanding access to this groundbreaking treatment.
Advancing Clinical Trials
Zymeworks maintains a robust pipeline of wholly-owned product candidates, showcasing significant potential across various indications. The organization is pushing forward with Phase 1 studies for two investigational drugs, ZW171 and ZW191, while also preparing for an investigational new drug application for ZW251 scheduled for mid-2025.
What sets Zymeworks apart is not just its innovative products but also its strategic partnerships with leading biopharmaceutical firms, which enhance its ability to deliver groundbreaking therapies to the marketplace.
Contact Information
If you have any inquiries about investor relations or media, feel free to reach out:
Investor inquiries:
Shrinal Inamdar
Senior Director, Investor Relations
(604) 678-1388
ir@zymeworks.com
Media inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com
Frequently Asked Questions
What are the upcoming events Zymeworks will attend?
Zymeworks will participate in the Jefferies Global Healthcare Conference, the Goldman Sachs Global Healthcare Conference, and the Citi European Healthcare Conference.
What is Zymeworks' primary focus?
The company focuses on developing innovative biotherapeutics for difficult-to-treat conditions, particularly cancer and autoimmune diseases.
What is zanidatamab?
Zanidatamab is a HER2-targeted bispecific antibody developed by Zymeworks, recently approved for the treatment of certain biliary tract cancers.
How does Zymeworks approach drug development?
Zymeworks utilizes a fully integrated drug development engine, allowing for the precision engineering of antibody-based therapies.
How can I get more information about Zymeworks?
For more details, visit their website at www.zymeworks.com or follow them on social media platforms.
